Skip to main content

Table 2 Initial data set and validation set results according to axillary nodal involvement

From: Lymph node positivity in different early breast carcinoma phenotypes: a predictive model

  Initial set Validation set
pN0 i+/mi/macro pN0 i+/mi/macro
Nb % Nb % p Nb % Nb % p
Nb patients 5507   2874    2746   1445   
Age median (range) 59 (18–101) 55 (20–98)   59 (18–100) 56 (22–90)  
<  60 3001 55 1856 65 < 0.0001 1464 53 910 63 < 0.0001
 61–65 818 15 348 12   443 16 201 14  
 >  65 1686 31 669 23   836 30 334 23  
Tumor size (median) 12   19    12   20   
<  10 2642 49 494 17 < 0.0001 1340 49 225 16 < 0.0001
 11 to 20 2185 40 1183 41   1081 40 604 42  
 >  20 608 11 1176 41   294 11 601 42  
Tumor type
 Ductal 4244 77 2278 79 < 0.0001 2133 78 1138 79 < 0.0001
 Lobular 711 13 399 14   332 12 203 14  
 Mixt 73 1 71 2   38 1 44 3  
 Others 473 9 126 4   241 9 59 4  
Grade
 1 2142 39 749 26 < 0.0001 1007 37 348 24 < 0.0001
 2 2410 44 1390 49   1245 46 711 49  
 3 887 16 724 25   459 17 378 26  
LVI
 Negative 4077 89 1584 59 < 0.0001 2004 89 765 58 < 0.0001
 Positive 510 11 1085 41   256 11 549 42  
Estrogen receptors
 negative 747 14 399 14 0.6964 371 14 213 15 0.296
 positive 4757 86 2470 86   2371 86 1230 85  
Progesterone receptors
 negative 1568 30 713 26 0.0004 782 30 401 29 0.6346
 positive 3678 70 2023 74   1841 70 980 71  
Hormonal receptors
 negative 660 12 360 13 0.4835 337 12 184 13 0.6948
 positive 4841 88 2508 87   2406 88 1258 87  
Her2 status
 negative 5837 91 1733 87 < 0.0001 2909 92 871 86 < 0.0001
 positive 563 9 248 13   269 8 142 14  
Tumor sub types
 Luminal A 4100 75 1926 67 < 0.0001 2029 75 943 66 < 0.0001
 Luminal B Her2- 364 7 392 14   217 8 205 14  
 HR+ Her2+ 336 6 185 6   140 5 105 7  
 HR- Her 2+ 151 3 137 5   93 3 69 5  
 Triple Negative 509 9 223 8   244 9 115 8  
Clinical size
 T0 1458 28 373 14 < 0.0001 756 29 177 13 < 0.0001
 T1 3166 61 1378 50   1565 60 675 48  
 T2 546 11 837 30   272 10 460 33  
  > T3 18 0 169 6   16 1 80 5